

ASX Code: GSS

19 November 2021

Results of 2021 Annual General Meeting

In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, we advise details of the resolutions and the proxies received in respect of each resolution are set out in the attached proxy summary.

Regards,

Peter Manley

Company Secretary

For further information, see our website (www.geneticsignatures.com) or contact us as below:

Dr John Melki

Chief Executive Officer

john.melki@geneticsignatures.com

T: +61 (0)2 9870 7580

Peter Manley
Chief Financial Officer

peter.manley@geneticsignatures.com

About Genetic Signatures Limited: Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, *3base*™. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the *EasyScreen*™ brand. Genetic Signatures' proprietary MDx *3base*™ platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures' current target markets are major hospital and pathology laboratories undertaking infectious disease screening.

Genetic Signatures Limited Annual General Meeting Friday, 19 November 2021 Results of Meeting

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

| Resolution Resolution Resolution Type For Against Proxy's Discretion Abstain For Against Abstain* Carried / Not Carried |
|-------------------------------------------------------------------------------------------------------------------------------------------------|
| Michael Aicher Ordinary 86.60% 13.31% 0.10% 86.48% 13.52% Carried 86.48% 13.52% |
| |
| |
| 3. Election of a Director - Dr Neil Gunn |
| Approval for the issue of Options to a Director, Dr Neil Ordinary 99.54% 239,230 89,458 1,426,850 71,764,393 99.25% 545,160 1,426,850 Carried |